Eurofins Expands Dungarvan Facilities
Eurofins Lancaster Laboratories, a part of Eurofins Scientific, has announced the expansion of its Dungarvan campus. The expansion includes a new building and an expansion of existing facilities.
Eurofins Lancaster Laboratories, a part of Eurofins Scientific (Paris, France), has announced the expansion of its Dungarvan campus (Ireland). The expansion includes a new building and an expansion of existing facilities.
“This expansion is the result of successfully growing strategic partnerships with our clients and the value we bring to them and their target markets,” said Timothy S. Oostdyk, Chairman, Eurofins Lancaster Laboratories, and Group Senior Vice President, Eurofins BioPharma Product Testing.
Building works are expected to commence in the fourth quarter of 2016 and will expand the existing facilities from a 2700 m2 laboratory to a 9000 m2 facility, focused on the biopharmaceutical industry in Ireland and the UK.
Carmel Fitzpatrick, Managing Director of Eurofins Lancaster Laboratories, Ireland, highlighted the commitment and technical capabilities of Eurofins staff. “We invest heavily in our internal training programmes, and we are grateful to be supported by the IDA and the Skillnets to deliver technical competency in our team that is world class,” commented Fitzpatrick.
The expansion will increase Eurofins Dungarvan based workforce to over 500 by 2021, including the 175 new jobs created within the past 24 months. An achievement not lost on Mary Mitchell O’Connor, Minister for Jobs, Enterprise, and Innovation who enthused, “It’s great to see an established successful company like Eurofins expanding its operations further in Waterford.”
For more information about Eurofins, please visit www.eurofins.com
AI and GenAI Applications to Help Optimize Purification and Yield of Antibodies From Plasma
October 31st 2024Deriving antibodies from plasma products involves several steps, typically starting from the collection of plasma and ending with the purification of the desired antibodies. These are: plasma collection; plasma pooling; fractionation; antibody purification; concentration and formulation; quality control; and packaging and storage. This process results in a purified antibody product that can be used for therapeutic purposes, diagnostic tests, or research. Each step is critical to ensure the safety, efficacy, and quality of the final product. Applications of AI/GenAI in many of these steps can significantly help in the optimization of purification and yield of the desired antibodies. Some specific use-cases are: selecting and optimizing plasma units for optimized plasma pooling; GenAI solution for enterprise search on internal knowledge portal; analysing and optimizing production batch profitability, inventory, yields; monitoring production batch key performance indicators for outlier identification; monitoring production equipment to predict maintenance events; and reducing quality control laboratory testing turnaround time.
